NEW YORK (GenomeWeb News) – French theranostics and IVD firm Theradiag will distribute Luminex's xTAG RVP and xTAG GPP assays in France, the companies said recently.
Luminex's xTAG RVP is a qualitative multiplex molecular diagnostic assay for the simultaneous detection of 19 viral types and subtypes from nasopharyngeal swabs, nasal aspirates, and bronchoalveolar lavages from individuals suffering from respiratory tract infections.
Meantime, the xTAG GPP identifies a variety of pathogens that cause gastroenteritis, and is the first molecular diagnostic kit covering over 90 percent of infections caused by bacteria, viruses, and parasites in a single test.
Further financial and other terms of the agreement were not disclosed.
Theradiag has been using Luminex’s multiplex technology to develop its own range of diagnostic kits for autoimmune diseases diagnosis since 1999.
"These new assays complement our growing portfolio of innovative IVD products using multiplex technology and strengthen our position in the expanding molecular diagnostic market," Theradiag CEO Michel Finance said in a statement.
In December, Luminex said that it would be moving to a direct sales channel for its molecular diagnostic products.
This story was updated from a previous version to provide additional information.